GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Ganciclovir

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons

Cytovene-IV

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Cytovene-IV - product and source limitations

Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.

Before applying: Verify the current prescribing information for this presentation.

Also check: Cytovene-IV - product and source limitations

Official source

Cytovene-IV - labeled renal guidance

Renal action and limits

Ganciclovir (Cytovene-IV), adult IV induction or maintenance for labeled CMV indications
Cockcroft-Gault creatinine clearance, mL/min

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Action or finding
For adult intermittent hemodialysis (HD), induction must not exceed 1.25 mg/kg IV after HD three times weekly. Maintenance must not exceed 0.625 mg/kg IV after HD three times weekly. At CrCl 50-69, induction is 2.5 mg/kg every 12 hours and maintenance 2.5 mg/kg daily; at 25-49, use 2.5 and 1.25 mg/kg daily, respectively; at 10-24, use 1.25 and 0.625 mg/kg daily.
Limits and monitoring
Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.
Before use
Verify the current prescribing information for this presentation.

Prescribing information revised 07/2017 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Ganciclovir (Cytovene-IV), adult IV induction or maintenance for labeled CMV indications
Renal measure
Cockcroft-Gault creatinine clearance, mL/min
Source revision
Prescribing information revised 07/2017
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2, adult renal dosage table and hemodialysis

Limits that apply to these rows

Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.

Adult renal dosing in this source
Adult CrCl (mL/min)Induction, IV over 1 hourMaintenance, IV over 1 hour
50-692.5 mg/kg every 12 hours2.5 mg/kg every 24 hours
25-492.5 mg/kg every 24 hours1.25 mg/kg every 24 hours
10-241.25 mg/kg every 24 hours0.625 mg/kg every 24 hours
<10, on HD1.25 mg/kg after HD, 3 times weekly0.625 mg/kg after HD, 3 times weekly
Read the retained text before reformatting

For adult intermittent hemodialysis (HD), induction must not exceed 1.25 mg/kg IV after HD three times weekly. Maintenance must not exceed 0.625 mg/kg IV after HD three times weekly. At CrCl 50-69, induction is 2.5 mg/kg every 12 hours and maintenance 2.5 mg/kg daily; at 25-49, use 2.5 and 1.25 mg/kg daily, respectively; at 10-24, use 1.25 and 0.625 mg/kg daily. Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.

Source revision: Prescribing information revised 07/2017 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019661s036lbl.pdf

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Cytovene-IV - labeled renal guidance

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Cytovene-IV - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

Ganciclovir (Cytovene-IV), adult IV induction or maintenance for labeled CMV indications

Renal method: Cockcroft-Gault creatinine clearance, mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Cytovene-IV - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ganciclovir (Cytovene-IV), adult IV induction or maintenance for labeled CMV indications

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Cytovene-IV - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Cytovene-IV - product and source limitations

Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.

How to use this: Verify the current prescribing information for this presentation.

Cytovene-IV - labeled renal guidanceCytovene-IV - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeCytovene-IV - labeled renal guidanceCytovene-IV - selected RX renal passageUCSF - intravenous ganciclovir
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Original oral ganciclovir schedules are not oral valganciclovir schedules. The source grouping of HD and PD is preserved and flagged for modality-specific revalidation.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/ganciclovir/

Usual Dosing (Adults)

CMV retinitis source summary: IV induction 5 mg/kg every 12 hours for 14 to 21 days; maintenance 5 mg/kg every 24 hours. Oral ganciclovir: 1 g every 8 hours or 500 mg every 3 hours (six doses/day), with food.

Do not give CYTOVENE-IV rapidly or as IV bolus: excessive levels increase toxicity. IM/subcutaneous injection of reconstituted pH 11 solution can cause severe tissue irritation. Do not exceed recommended dose or infusion rate.

Retinitis with normal renal function: induction 5 mg/kg IV at constant rate over 1 hour every 12 hours for 14 to 21 days. Maintenance 5 mg/kg over 1 hour daily seven days/week or 6 mg/kg daily five days/week. Reinduction is recommended for progression during maintenance.

Transplant CMV prevention, normal function: 5 mg/kg IV over 1 hour every 12 hours for 7 to 14 days, then 5 mg/kg daily seven days/week or 6 mg/kg daily five days/week. Duration depends on degree/duration of immunosuppression. Bone-marrow allograft trials continued to days 100 to 120; several patients stopping early developed CMV. Heart allograft patients developed new CMV after therapy stopped on day 28, suggesting need for continued dosing to prevent late disease.

GRPH-ganciclovir-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl (mL/min)IV inductionIV maintenanceOral ganciclovir
>70No changeNo changeNo change
50 to 692.5 mg/kg every 12 hours2.5 mg/kg every 24 hours1500 mg daily or 500 mg three times daily
25 to 492.5 mg/kg every 24 hours1.25 mg/kg every 24 hours1000 mg daily or 500 mg twice daily
10 to 241.25 mg/kg every 24 hours0.625 mg/kg every 24 hours500 mg daily
<101.25 mg/kg three times/week after dialysis0.625 mg/kg three times/week after dialysis500 mg three times/week after dialysis
GRPH-ganciclovir-02 · Source section: Renal DosingRenal section finder

Hemodialysis

The source groups hemodialysis and peritoneal dialysis together: IV induction 1.25 mg/kg three times/week following dialysis; IV maintenance 0.625 mg/kg three times/week following dialysis; oral 500 mg three times/week following dialysis.

GRPH-ganciclovir-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Cytovene-IV - labeled renal guidance

Open original reference

Open / share this exact local source

FDA / product prescribing information · Ganciclovir (Cytovene-IV), adult IV induction or maintenance for labeled CMV indications

Renal method: Cockcroft-Gault creatinine clearance, mL/min
Source date: Prescribing information revised 07/2017
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2, adult renal dosage table and hemodialysis

Limits that apply to these rows

Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.

Adult renal dosing in this source
Adult CrCl (mL/min)Induction, IV over 1 hourMaintenance, IV over 1 hour
50-692.5 mg/kg every 12 hours2.5 mg/kg every 24 hours
25-492.5 mg/kg every 24 hours1.25 mg/kg every 24 hours
10-241.25 mg/kg every 24 hours0.625 mg/kg every 24 hours
<10, on HD1.25 mg/kg after HD, 3 times weekly0.625 mg/kg after HD, 3 times weekly
Read the retained text before reformatting

For adult intermittent hemodialysis (HD), induction must not exceed 1.25 mg/kg IV after HD three times weekly. Maintenance must not exceed 0.625 mg/kg IV after HD three times weekly. At CrCl 50-69, induction is 2.5 mg/kg every 12 hours and maintenance 2.5 mg/kg daily; at 25-49, use 2.5 and 1.25 mg/kg daily, respectively; at 10-24, use 1.25 and 0.625 mg/kg daily. Infuse over one hour. Check CrCl and blood counts. The label's nondialysis table separates induction from maintenance; dosing below CrCl 10 without HD is not supplied by the HD row.

RDM73-cytovene-official-1 · Source locator: Renal guidance: 2, adult renal dosage table and hemodialysis

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019661s036lbl.pdf
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault creatinine clearance, mL/min
Source date/version
Prescribing information revised 07/2017
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
e3622966fe32c2b7fbe14faf2aa97fb5e6ab4fec4c41b3e450ec2be9438554a7
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Cytovene-IV - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ganciclovir (Cytovene-IV), adult IV induction or maintenance for labeled CMV indications

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror lists the distinct post-HD induction and maintenance ceilings and their three-times-weekly schedules.

RDM73-cytovene-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cytovene-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
b9f6f16f6d130663d0a0b59049519c05f68ac15992e2f5b2ce2edc4f5ab3bdab
Separate professional-source layer

University and professional protocols

Professional

UCSF - intravenous ganciclovir

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Exactly 70 is unassigned. Use total body weight unless >120% of ideal, then adjusted weight per this source. Continuous-flow changes require reassessment.

CMV treatment - IV
CrCl, mL/minSource-specific dose / instruction
>705 mg/kg every 12 hours
50-692.5 mg/kg every 12 hours
25-492.5 mg/kg every 24 hours
10-241.25 mg/kg every 24 hours
CMV prevention - IV
CrCl, mL/minSource-specific dose / instruction
>705 mg/kg every 24 hours
50-692.5 mg/kg every 24 hours
25-491.25 mg/kg every 24 hours
10-240.625 mg/kg every 24 hours
Dialysis guidance - separate source-specific schedules
Ganciclovir dialysis
Dialysis setting / indicationSource-specific schedule
IHD treatment1.25 mg/kg initially and after HD
IHD prevention0.625 mg/kg initially and after HD
Continuous HD treatment2.5 mg/kg every 12 hours
Continuous HD prevention2.5 mg/kg every 24 hours
Read the retained text before reformatting

CrCl bands: >70 / 50-69 / 25-49 / 10-24 mL/min. CMV treatment: 5 mg/kg every 12 hours / 2.5 mg/kg every 12 hours / 2.5 mg/kg daily / 1.25 mg/kg daily. Prevention: 5 / 2.5 / 1.25 / 0.625 mg/kg daily. Exactly 70 is not assigned in the displayed bands.

Intermittent-HD treatment: 1.25 mg/kg initially and after HD; prevention: 0.625 mg/kg initially and after HD. Continuous-HD treatment: 2.5 mg/kg every 12 hours; prevention: 2.5 mg/kg daily. Continuous-flow changes require individualized reassessment.

Use total body weight unless it exceeds 120% of ideal body weight, when the source uses adjusted weight. All doses here are IV.

RDM30-027-ganciclovir-1 · Source locator: UCSF - intravenous ganciclovir; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ganciclovir
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
5c806946aa388e15640aabb9656efa0dd16e11727cd07a9f8fcff2a822d3a96e

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/ganciclovir/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
0dd11291676c4a8f22d11e3061e702f3bc5d417cfc4e5b62289aacd88a462724
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top